Real-World Study of DLBCL With Different Genetic Subtypes
Recruiting
Observational Study
DLBCL - Diffuse Large B Cell Lymphoma
Lymphoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 10,000 (estimated)
- Sponsor
- Ruijin Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
To collect and evaluate the data of real-world treatment regimen, efficacy, safety and survival information of DLBCL patients with different genetic suptypes
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Histologically-confirmed diffuse large B-cell lymphoma (DLBCL)
* Genetic subtype belonging to at least one of the seven subtypes by using next generation sequencing: MCD, BN2, N1, ST2, A53, EZB (MYC+, MYC-) and others
* Fully comprehension and signature of the informed consent…
Contacts